Background. Patients on maintenance haemodialysis are at high risk of aluminium overload. While deferoxamine (DFO) has potential adverse effects, lower DFO dosages may afford good efficacy with fewer side effects. We evaluated the therapeutic response of low-dose (2.5 mg/kg/ week) DFO among haemodialysis patients with aluminium overload. Methods. We recruited the participants via basal predialysis serum aluminium (Al) levels of ≥20 μg/L with clinical suspicion of aluminium toxicity or hyperparathyroidism indicating parathyroidectomy and positive DFO tests. Patients were randomly divided into standard-dose (5 mg/kg/ week) and low-dose (2.5 mg/kg/week) groups. We compared the differences of mineral biochemical and haematological parameters before and after DFO treatment. Successful treatment was defined as a serum aluminium increase of <50 μg/L by DFO test. Adverse events during DFO therapy between the groups were also compared. Results. In total, 42 haemodialysis patients completed treatment (standard-dose group, n = 21; low-dose group, n = 21). The demographic characteristics of the groups did not differ. Serum corrected calcium and ferritin decreased in both groups, while serum total alkaline phosphatase increased in both groups. Serum phosphorus increased in low-dose group (P = 0.029), while plasma intact parathyroid hormone increased in standard-dose group (P = 0.004). The successful treatment response rates did not differ between the two groups (standard-dose: 12/21, 57% vs low-dose: 13/21, 62%; P = 0.75). Conclusions. Low-dose DFO may offer similar therapeutic effects as standard-dose DFO therapy.
Introduction
Dialysis patients are at high risk for aluminium overload [1] due to long-term use of aluminium-containing phosphate binders [2, 3] , poor renal excretion of aluminium and contact with aluminium-containing dialysate. The Kidney Disease Outcomes Quality Initiative (K/DOQI) recommends deferoxamine (DFO) for treatment of dialysis patients with aluminium overload [4] . However, DFO has side effects of its own [5] , such as itchy skin, nausea, myalgia and neurotoxicity [6] . Although most of these side effects are mild and reversible, severe or even life-threatening side effects are possible, especially anaphylactic shock and mucormycosis [7, 8] , even though these are rare. Because of the common side effects of DFO, dosing of 20 to 40 mg/kg of body weight [9] [10] [11] was abandoned. The toxicity of DFO is dose-dependent, and thus, many studies were designed to find the optimal dosage for aluminium overload treatment [12] [13] [14] . According to the recent K/DOQI clinical practice guidelines, the DFO standard dosage is 5 mg/kg of body weight [4] . Furthermore, several pharmacokinetic and small-scale, short-term studies found that even lower doses than 5 mg/kg could be as efficacious as the standard 5 mg/kg dose [15, 16] , but clinical trials verifying its efficacy at lower doses are lacking. Therefore, we compared the treatment response to standard-dose (5 mg/kg) versus lower-dose (2.5 mg/kg) DFO among dialysis patients with aluminium overload during 2 months of treatment.
Materials and methods
In this prospective study, we enrolled haemodialysis patients with aluminium overload in an 83-bed haemodialysis unit via annual serum aluminium screening and further confirmatory DFO testing in July 2007 and July 2008. The study protocol was approved by the Institutional Review Board of Chi-Mei Medical Center. All the patients gave written informed consent to participate.
Patients
Patients with basal predialysis serum Al levels of ≥20 μg/L with (i) clinical suspicion of aluminium toxicity or (ii) high plasma intact parathyroid hormone (iPTH) levels (>800 pg/mL) indicating the need for parathyroidectomy (PTX) were included. Aluminium toxicity included signs and symptoms of general bone pain or proximal muscle weakness, easy fracture, progressive cognitive dysfunction, unexplained hypercalcaemia and microcytic anaemia without iron deficiency [5] . High plasma iPTH levels, in association with hypercalcaemia or hyperphosphataemia refractory to medical therapy, indicated the need for PTX. According to the K/DOQI guidelines, a DFO test should be done, if existence of clinical signs and symptoms of aluminium toxicity with suspicion, or prior to parathyroid surgery if the patient has had aluminium exposure. A positive DFO test [post-DFO (5 mg/kg) challenge, serum aluminium increment ≥50 μg/L] was used to diagnose aluminium overload.
The patients who had known previous intolerance to DFO or who previously developed DFO side effects such as allergic reactions, neurological symptoms or obvious gastrointestinal (GI) upset were excluded. Patients who suffered from active medical problems, such as infection, acute coronary syndrome and GI bleeding 3 months prior to this study, were also excluded.
DFO treatment
Forty-four haemodialysis patients were enrolled, and then randomly divided into two groups: the standard-dose (5 mg/kg/week) and the low-dose (2.5 mg/kg/week) groups. Two weeks before the study, aluminium-containing phosphate binders were stopped. Some medications routinely used in haemodialysis patients can influence mineral biochemical parameters. These include calcium bicarbonate, vitamin D3 and non-calcium, non-aluminium phosphate binders. To reduce the confounding effect of these concomitant medications, fixed doses of calcium bicarbonate were given to suitable patients during the study of DFO treatment (Table 1) . Other medications, such as vitamin D3 and non-calcium, non-aluminium phosphate binders were withheld for 2 weeks before starting the study.
All of the haemodialysis patients underwent three times weekly highflux dialysis with polysulfone APS series dialysis filters (Asahi Kasei Kuraray Medical Co., Asahi, Japan) to establish similar serum aluminium removal rates. DFO purchased from Ciba-Geigy was administered once per week to the two groups at the two different doses (5.0 and 2.5 mg/ kg/week, respectively) for a total of 2 months according to the K/DOQI guidelines. In some patients with iron deficiency, when DFO was given once weekly, intravenous iron supplementation was withheld at that time.
Based on previous studies, several mineral biochemical and haematological parameters, such as decreased serum calcium levels, increased total alkaline phosphatase (tAP) and iPTH levels and increased haematocrit improved significantly after DFO treatment among patients with aluminium overload [17] . Thus, we compared these parameters between the two groups as measures of therapeutic effectiveness. In addition, we analyzed the differences in the 2nd DFO test between the groups according to the K/DOQI guidelines and also the differences in laboratory data between the two groups.
Adverse event reporting
During the 2-month treatment period, any symptom after DFO use was recorded based on a questionnaire. In order to reduce investigator subjectivity, reporting of adverse events was done using a double-blind design. The adverse event questionnaires were administered by two well-trained examiners who were 'blind' to the treatment dose, as were the enrolled patients. The examiners also encouraged the patients to recall only the symptoms occurring after DFO use. The adverse events thought due to DFO in each group were recorded for further comparison.
Laboratory methods
Laboratory studies included serum corrected calcium (cCa), phosphorus, the product of total corrected calcium times phosphorus (cCa × P), tAP, iPTH, ferritin and hematocrit.
Serum cCa was calculated as follows:
½cCa mg=dL = ½Ca mg=dL; if serum albumin ≥4 g=dL and ½cCa mg=dL = ½Ca mg=dL + 0:8½4 À serum albumin; g=dL; if serum albumin < 4 g=dL:
Serum cCa, phosphorus and tAP levels were measured by an automated chemistry analyzer (Hitachi 7600 Automatic Analyzer, Hitachi, Japan). Albumin levels were determined by the bromcresol green method. Plasma levels of iPTH were measured with a commercially available two-site immunoradiometric assay (IRA, CIS Bio international, Saclay, France). Serum ferritin levels were measured with an IRA method (Immunotech, Marseille, France). Plasma aluminium levels were determined using transverse-heated graphite atomizer graphite tubes with the technique of graphite furnace atomic absorption spectrophotometry (AAnalyst 800, Perkin Elmer, Manasquan, New Jersey, USA).
Statistical analysis
All continuous variables were expressed as means ± standard deviations (SDs) and compared using Student's t or paired t-tests (data were checked for normal distributions via the Kolmogorov-Smirnov Z test). Ordinal demographic data were analyzed via the χ 2 test or Fisher's exact test. The major statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chicago, IL, USA). A P value of <0.05 was considered statistically significant.
Results

Demographic characteristics
In July 2007 and July 2008, a total of 473 haemodialysis patients underwent annual serum aluminium testing in an 83-bed haemodialysis unit. Of these, 44 patients met the Table 1 . Demographic data of study population in the standard-dose (5 mg/kg) and low-dose (2.5 mg/kg) DFO groups (n = 42) 5 mg/kg DFO (n = 21) 2.5 mg/kg DFO (n = 21) P inclusion criteria for the study. These 44 patients were randomly divided into two groups, including the standarddose (S) group (n = 22) and low-dose (L) group (n = 22). During the 2-month treatment period, two of the patients dropped out of the study due to intolerable DFO side effects. One patient in group S had drowsy consciousness after DFO use, with suspected neurological symptoms, and another patient in group L had GI upset and requested to drop out of the study. The demographic characteristics of both groups (21 patients in each group) did not differ significantly ( Table 1) .
Analysis of laboratory data before and after DFO treatment
The mineral biochemical and haematological parameters before and after DFO treatments were compared within each group (Table 2) . Serum cCa and ferritin levels decreased dramatically and significantly in each group after DFO treatment. Serum tAP also increased dramatically and significantly in both groups. Serum phosphorus levels increased significantly in group L, while plasma iPTH increased significantly in group S. Other mineral biochemical data, including the product of total corrected calcium times phosphorus (cCa × P) and haematocrit, did not differ significantly before and after DFO treatment in either group.
Therapeutic effectiveness and adverse events of DFO treatments by dosage
Before DFO treatment, serum basal Al levels did not differ between the two groups (Table 3) . After 2 months of treatment, according to the K/DOQI guidelines, successful treatment of aluminium overload is defined as a serum aluminium increase of <50 μg/L by the DFO test. The difference in serum aluminium (ΔAl) levels by the standard DFO test did not differ statistically between the two groups before and after DFO treatment (Table 3) . Of the 42 patients in both groups, 25 had 'treatment successes' after completion of DFO treatment (group S: n = 12/21, 57%; group L: n = 13/21, 62%; P = 0.75). Treatment success did not differ between the groups. We also Values are expressed as means ± SDs. cCa × P, Serum corrected calcium times phosphorus product; iPTH, intact parathyroid hormone. Values are expressed as means ± SDs. cCa × P, Serum corrected calcium times phosphorus product; iPTH, intact parathyroid hormone. compared the differences in biochemical and haematological data between the two groups, and these parameters did not differ (Table 4) . Our results imply that the two dosage groups had similar efficacy rates. Adverse events in each group were also recorded after DFO treatments (Table 5 ). These events included itchy skin, constitutional symptoms, neurologic symptoms, GI symptoms and others.
Discussion
Most previous studies of aluminium overload treatment with low-dose DFO (<5 mg/kg/week) were small-scale, short-term studies [15, 16] . Based on these previous studies, low-dose DFO could offer potentially similar therapeutic effectiveness to the standard dosage. Our study was designed according to the K/DOQI guidelines for aluminium overload. Our results showed that low-dose (2.5 mg/kg) DFO had similar effectiveness to the standard 5-mg/kg DFO dose for reducing aluminium overload.
After completing DFO treatments, several mineral biochemical and haematological parameters improved significantly among the patients with aluminium overload, including decreased serum calcium levels and increased tAP levels [17] ; these findings reflect improvement in low bone turnover status. Serum ferritin level decreased significantly in both groups, which is also compatible with the iron-chelating effect of DFO. Our study also showed similar findings.
Nonetheless, our results differ from those of previous studies in several ways. At first, high average plasma iPTH levels were noted in both dosage groups, which could have been due to enrolling patients with hyperparathyroidism, prior to PTX. These patients did not previously receive calcimimetic therapy, which was not available in Taiwan during the study period. After standard-dose DFO treatment, the plasma iPTH levels increased significantly. One of the possible reasons could be the inhibitory effect of aluminium on parathyroid gland function [18] . Another study showed similar findings regarding hyperparathyroidism after aluminium depletion [19] . It is possible that DFO treatment aggravates hyperparathyroidism before PTX. Therefore, low-dose DFO treatment could cause less parathyroid stimulation in this situation. On the other hand, serum phosphorus levels increased significantly in the low-dose DFO group, possibly due to the 'rebound' effect of discontinuing aluminium-containing phosphate binder use before this study.
It is a worldwide trend to reduce aluminium exposure to dialysis patients. While aluminium-based phosphate binders used as short-term therapy were suggested by the K/DOQI guidelines, these medications are prohibited in some countries [20] . The non-calcium, non-aluminium phosphate binders (such as sevelamer hydrochloride, lanthanum carbonate) are suggested for use instead. However, these newly developed medications have not become popular in many countries due to their high cost [20] . In addition, the source of aluminium may contribute to extra aluminium intake from other medications [21] . Therefore, aluminium overload is still a potential problem among the dialysis population. Low-dose DFO treatment, if it offers good efficacy with fewer side effects, in combination with aluminium gel use, could be an alternative method for management of calcium-phosphorus imbalance disorders.
Our study had several limitations. Firstly, the study groups were not well matched due to the limited numbers of patients, especially for duration of the preceding dialysis treatment and the presence of diabetes mellitus (DM). However, for better reliability, the adverse event questionnaires were administered by two well-trained examiners who were 'blind' to the treatment regimen and encouraged the patient to recall the symptoms only occurred after DFO use. In addition, some of the reported symptoms appeared to be positively correlated to DM. In our study, patients in the low-dose DFO group had a higher frequency of DM than patients in the standarddose group, but the low-dose DFO group appeared to have fewer adverse events. Furthermore, we stratified the patients into DM and non-DM subgroup for analysis. In both subgroups, the result showed no statistical significance about all the reported symptoms between different treatment-dose groups. Besides, the 'treatment success' was also compared in DM and non-DM subgroups, which still showed no difference at all. A lack of statistical power is one probable cause for the lack of statistical significant for adverse events between the groups, along with the relatively low incidence of DFO side effects. Secondly, due to the lack of bone biopsy being used as the gold standard for diagnosis of aluminium bone disease, we relied on mineral biochemical and hematological parameters as indirect markers of aluminium overload improvement. Additionally, some of the patients enrolled in our study had hyperparathyroidism, which could have reduced the effects of DFO on the improvement of low-turnover bone disease.
In conclusion, our preliminary study implied that treatment responses for low-and standard-dose DFO did not differ. We conducted this study, even though we enrolled a limited number of patients, resulting in low statistical power. We believe that it will become more difficult to investigate aluminium toxicity in the future due to its decreasing incidence in many countries, even though aluminium-based medications are still widely used as phosphate binders in many developing or under-developed countries. Based on our results, and in combination with previous small-scale, short-term studies, we hope to offer low-dose DFO therapy as an alternative treatment for aluminium toxicity among haemodialysis patients. A larger prospective trial using bone biopsy as the gold standard for aluminium-related bone disease would afford further confirmation.
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